Clinical Trials
29
Trial Phases
4 Phases
Drug Approvals
5
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: CREXONT ER
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06765668
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Parkinson's Research Centers of America - Orange County, Aliso Viejo, California, United States
🇺🇸Parkinson's Research Centers of America - Palo Alto, Palo Alto, California, United States
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT06161220
- Locations
- 🇺🇸
AXIS Clinicals, LLC, Dilworth, Minnesota, United States
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT03877510
- Locations
- 🇺🇸
Xenoscience, Inc (102), Phoenix, Arizona, United States
🇺🇸St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (156), Phoenix, Arizona, United States
🇺🇸Clinical Trials, Inc (113), Little Rock, Arkansas, United States
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
- Conditions
- Parkinson's Disease (Disorder)
- Interventions
- Drug: IPX203 ER CD-LDDrug: IR CD-LDOther: Placebo Matching IR CD-LDOther: Placebo Matching IPX203
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 630
- Registration Number
- NCT03670953
- Locations
- 🇺🇸
Xenoscience, Inc. (102), Phoenix, Arizona, United States
🇺🇸St. Joseph's Hospital & Medical Center/ Barrow Neurological Institute (156), Phoenix, Arizona, United States
🇺🇸Clinical Trials, Inc. (113), Little Rock, Arkansas, United States
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE
- Conditions
- Migraine
- Interventions
- Drug: Placebo ZNSDrug: ZNS
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Impax Laboratories, LLC
- Target Recruit Count
- 374
- Registration Number
- NCT03275922
- Locations
- 🇺🇸
Phoenix Children's Hospital (149), Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital (109), Little Rock, Arkansas, United States
🇺🇸Advanced Research Center, Inc (134), Anaheim, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next